SELECT ($NYSE:SEM): MEDICAL reported second-quarter FY2023 total revenue of USD 1674.5 million, a 5.7% year-over-year increase, along with a net income of USD 78.2 million, a 41.7% year-over-year increase, for the period ending June 30 2023.
On Thursday, SELECT MEDICAL reported the record revenue and net income for the second quarter of fiscal year 2023. This announcement resulted in the stock opening at $30.2 and closing at $30.4, representing a modest 0.3% increase from its prior price of $30.4. This was the highest quarterly earnings report for SELECT MEDICAL since its inception. The company’s impressive second-quarter results were driven by continued strong demand for their medical services and a focus on cost containment.
Moving forward, SELECT MEDICAL is optimistic about its prospects for the remainder of the fiscal year. The company is continuing to invest in new initiatives that will further improve its services and products, as well as pursuing strategic acquisitions to expand its market share. It is expected that these investments will pay off in the long run and help the company continue to grow and increase profits. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Select Medical. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Select Medical. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Select Medical. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Select Medical are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
After analyzing the fundamentals of SELECT MEDICAL, GoodWhale has concluded that the company has a high health score of 8/10 with regard to cashflows and debt, which is a reassuring indicator that it is capable to safely ride out any crisis without the risk of bankruptcy. With regard to its star classification, SELECT MEDICAL falls into the ‘rhino’ category, indicating that it has achieved moderate revenue or earnings growth. Given this assessment, it is likely that investors interested in long-term stability and value appreciation may be interested in SELECT MEDICAL. The company is strong in terms of its medium dividend, growth, profitability, and weak in asset. More…
Risk Rating Analysis
Star Chart Analysis
The company’s competitors include Eukedos SpA, Med Life SA, Athens Medical Centre SA, and other similar companies.
Eukedos SpA is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of rare diseases. The company has a market cap of 28.09M as of 2022 and a Return on Equity of 10.29%. Eukedos SpA is headquartered in Milan, Italy.
MedLife SA is a publicly traded company with a market capitalization of 2B as of 2022. The company’s return on equity is 22.48%. MedLife SA is a leading provider of medical and healthcare services in South America. The company offers a full range of services including primary care, hospital care, specialty care, and behavioral health services. MedLife SA also has a strong presence in the insurance and managed care markets.
– Athens Medical Centre SA ($LTS:0ONM)
Athens Medical Centre SA is a medical company that operates in Greece. The company has a market cap of 117.53M as of 2022 and a return on equity of 18.02%. The company provides medical services and products to patients in Greece. Athens Medical Centre SA operates in the following segments: Medical Services, Medical Products, and Other. The Medical Services segment provides medical services to patients in Greece. The Medical Products segment provides medical products to patients in Greece. The Other segment includes activities such as real estate and investments.
SELECT MEDICAL reported strong financial results for the second quarter of FY2023 with total revenue growing 5.7% and net income increasing 41.7% year-over-year. This suggests that the company is well-positioned for growth, making it an attractive investment opportunity. The strong financial performance can be attributed to rising demand for their services, which suggests that the company is well-positioned to continue to experience growth in the coming quarters.
Investors should look favorably upon SELECT MEDICAL’s ability to generate revenue and profits, despite the uncertain economic environment. As the company continues to deliver strong financial results, investors should consider investing in SELECT MEDICAL for long-term growth.